Evaluation of a lateral thoracotomy implant approach for a centrifugal-flow left ventricular assist device: The LATERAL clinical trial

• Published in: The Journal of heart and lung transplantation Vol. 38; no. 4; pp. 344 - 351
• Main Authors: McGee, Edwin, Danter, Matthew, Strueber, Martin, Mahr, Claudius, Mokadam, Nahush A., Wieselthaler, Georg, Klein, Liviu, Lee, Sangjin, Boeve, Theodore, Maltais, Simon, Pretorius, G. Victor, Adler, Eric, Vassiliades, Thomas, Cheung, Anson
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2019
• Subjects: bridge to transplant; congestive heart failure; left ventricular assist device; mechanical circulatory support; minimally invasive; mechanical circulatory support; congestive heart failure; left ventricular assist device; minimally invasive; bridge to transplant
• ISSN: 1053-2498; 1557-3117
• DOI: 10.1016/j.healun.2019.02.002

The HeartWare centrifugal-flow ventricular assist device system (HVAD) is a viable option for treatment of advanced heart failure. There is a growing trend toward the use of less invasive techniques in cardiac surgery, and the thoracotomy technique for HVAD implantation may provide benefits not available with conventional approaches. The LATERAL trial is a multicenter, prospective, non-randomized, single-arm trial that utilized data from 144 patients enrolled in the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database at 26 centers in the United States and Canada. The primary composite end-point was success at 180 days defined as alive on the originally implanted device and free from disabling stroke (modified Rankin Scale score >3), transplanted or explanted for recovery. The key secondary end-point was mean length of initial hospital stay. The primary end-point was successfully achieved in 88.1% of patients and was significantly greater than the pre-defined performance goal of 77.5% set from historical sternotomy data (p = 0.0012). The key secondary end-point—mean length of initial hospital stay —was 18 days and was significantly shorter than the pre-defined performance goal of 26.1 days obtained from historical sternotomy data (p < 0.0001). The adverse event profile further demonstrated the safety of the thoracotomy approach. The overall patient survival was good, and bleeding requiring reoperation was significantly less frequent than that observed in previous studies using the sternotomy approach. This prospective clinical trial provides validation that implantation of the HVAD system via the thoracotomy approach used in the LATERAL study represents a safe and effective alternative to median sternotomy in selected patients intended for a bridge-to-transplant indication.